Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness.
Lin CP, Levy PL, Alflen A, Apriamashvili G, Ligtenberg MA, Vredevoogd DW, Bleijerveld OB, Alkan F, Malka Y, Hoekman L, Markovits E, George A, Traets JJH, Krijgsman O, van Vliet A, Poźniak J, Pulido-Vicuña CA, de Bruijn B, van Hal-van Veen SE, Boshuizen J, van der Helm PW, Díaz-Gómez J, Warda H, Behrens LM, Mardesic P, Dehni B, Visser NL, Marine JC, Markel G, Faller WJ, Altelaar M, Agami R, Besser MJ, Peeper DS. Lin CP, et al. Among authors: de bruijn b. Cancer Cell. 2024 Apr 8;42(4):623-645.e10. doi: 10.1016/j.ccell.2024.02.016. Epub 2024 Mar 14. Cancer Cell. 2024. PMID: 38490212 Free PMC article.
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.
Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Dagidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, Blank CU, Altelaar M, Schumacher TN, Peeper DS. Vredevoogd DW, et al. Among authors: de bruijn b. Cell. 2019 Jul 25;178(3):585-599.e15. doi: 10.1016/j.cell.2019.06.014. Epub 2019 Jul 11. Cell. 2019. PMID: 31303383 Free article.
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
Boshuizen J, Pencheva N, Krijgsman O, Altimari DD, Castro PG, de Bruijn B, Ligtenberg MA, Gresnigt-Van den Heuvel E, Vredevoogd DW, Song JY, Visser N, Apriamashvili G, Janmaat ML, Plantinga TS, Franken P, Houtkamp M, Lingnau A, Jure-Kunkel M, Peeper DS. Boshuizen J, et al. Among authors: de bruijn b. Cancer Res. 2021 Apr 1;81(7):1775-1787. doi: 10.1158/0008-5472.CAN-20-0434. Epub 2021 Feb 2. Cancer Res. 2021. PMID: 33531370
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling.
Apriamashvili G, Vredevoogd DW, Krijgsman O, Bleijerveld OB, Ligtenberg MA, de Bruijn B, Boshuizen J, Traets JJH, D'Empaire Altimari D, van Vliet A, Lin CP, Visser NL, Londino JD, Sanchez-Hodge R, Oswalt LE, Altinok S, Schisler JC, Altelaar M, Peeper DS. Apriamashvili G, et al. Among authors: de bruijn b. Nat Commun. 2022 Apr 8;13(1):1923. doi: 10.1038/s41467-022-29442-x. Nat Commun. 2022. PMID: 35395848 Free PMC article.
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.
Zhang Z, Kong X, Ligtenberg MA, van Hal-van Veen SE, Visser NL, de Bruijn B, Stecker K, van der Helm PW, Kuilman T, Hoefsmit EP, Vredevoogd DW, Apriamashvili G, Baars B, Voest EE, Klarenbeek S, Altelaar M, Peeper DS. Zhang Z, et al. Among authors: de bruijn b. Cell Rep Med. 2022 Jun 21;3(6):100655. doi: 10.1016/j.xcrm.2022.100655. Epub 2022 Jun 9. Cell Rep Med. 2022. PMID: 35688159 Free PMC article.
An adverse tumor-protective effect of IDO1 inhibition.
Kenski JCN, Huang X, Vredevoogd DW, de Bruijn B, Traets JJH, Ibáñez-Molero S, Schieven SM, van Vliet A, Krijgsman O, Kuilman T, Pozniak J, Loayza-Puch F, Terry AM, Müller J, Logtenberg MEW, de Bruijn M, Levy P, Körner PR, Goding CR, Schumacher TN, Marine JC, Agami R, Peeper DS. Kenski JCN, et al. Among authors: de bruijn b. Cell Rep Med. 2023 Feb 21;4(2):100941. doi: 10.1016/j.xcrm.2023.100941. Cell Rep Med. 2023. PMID: 36812891 Free PMC article.
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.
Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Dagidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, Blank CU, Altelaar M, Schumacher TN, Peeper DS. Vredevoogd DW, et al. Among authors: de bruijn b. Cell. 2020 Jan 23;180(2):404-405. doi: 10.1016/j.cell.2020.01.005. Cell. 2020. PMID: 31978349 Free article. No abstract available.
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.
Krijgsman O, Kemper K, Boshuizen J, Vredevoogd DW, Rozeman EA, Ibanez Molero S, de Bruijn B, Cornelissen-Steijger P, Shahrabi A, Del Castillo Velasco-Herrera M, Song JY, Ligtenberg MA, Kluin RJC, Kuilman T, Ross-Macdonald P, Haanen JBAG, Adams DJ, Blank CU, Peeper DS. Krijgsman O, et al. Among authors: de bruijn b. Clin Cancer Res. 2021 Oct 1;27(19):5389-5400. doi: 10.1158/1078-0432.CCR-20-4218. Clin Cancer Res. 2021. PMID: 34230026
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, van Akkooi ACJ, Flaherty KT, Boland GM, Peeper DS. Boshuizen J, et al. Among authors: de bruijn b. Nat Commun. 2023 Feb 7;14(1):672. doi: 10.1038/s41467-023-35852-2. Nat Commun. 2023. PMID: 36750559 Free PMC article. No abstract available.
45 results